40
Participants
Start Date
January 13, 2021
Primary Completion Date
October 31, 2027
Study Completion Date
October 31, 2027
ONO-4578
Specified dose on specified days
ONO-4538
Specified dose on specified days
Capecitabine
Specified dose on specified days
Oxaliplatin
Specified dose on specified days
Fluorouracil
Specified dose on specified days
Calcium Levofolinate Hydrateb
Specified dose on specified days
Bevacizumab
Specified dose on specified days
National Cancer Center Hospital East, Kashiwa-shi
Kobe City Hospital Organization Kobe City Medical Center General Hospital, Kobe
Kanagawa Cancer Center, Yokohama
Saitama Cancer Center, Ina
NHO Osaka National Hospital, Osaka
Osaka General Medical Center, Osaka
Osaka Medical and Pharmaceutical University Hospital, Takatsuki-shi
Saitama Medical University International Medical Center, Hidaka-shi
Cancer Institute Hospital of JFCR, Koto-Ku
Lead Sponsor
Ono Pharmaceutical Co. Ltd
INDUSTRY